Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Savara has a consensus rating of "Moderate Buy" from nine brokerages (1 sell, 1 hold, 6 buy, 1 strong buy) with an average 1-year analyst target of $9.00, versus a recent share price around $5.25.
• Large institutions built sizeable Q4 positions (e.g., Polar Capital ~$50M, RTW ~$36M, Marshall Wace ~$27M) and about 87.93% of the stock is held by hedge funds and other institutional investors.
• Savara is a clinical-stage biopharma whose lead candidate, Molgradex, is under regulatory review for autoimmune PAP; the company recently missed quarterly EPS (‑$0.13 vs. ‑$0.12) and analysts expect about ‑0.45 EPS for the fiscal year.

Savara Inc. (NASDAQ:SVRA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $9.00.

SVRA has been the topic of a number of research reports. Oppenheimer set a $10.00 target price on shares of Savara in a report on Tuesday, December 23rd. Guggenheim reiterated a "buy" rating on shares of Savara in a research report on Tuesday, December 23rd. Wells Fargo & Company boosted their price objective on Savara from $7.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday, December 18th. Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered Savara from a "hold" rating to a "sell" rating in a research note on Saturday, March 14th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SVRA. Polar Capital Holdings Plc bought a new position in Savara during the fourth quarter valued at $50,086,000. RTW Investments LP purchased a new position in shares of Savara during the 4th quarter worth about $35,893,000. VR Adviser LLC boosted its stake in shares of Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company's stock worth $20,256,000 after purchasing an additional 5,626,624 shares during the period. Marshall Wace LLP bought a new position in Savara during the 4th quarter valued at about $27,496,000. Finally, Spruce Street Capital LP bought a new position in Savara during the 4th quarter valued at about $14,539,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Stock Down 0.6%

NASDAQ SVRA opened at $5.25 on Friday. The stock has a 50 day moving average price of $5.55 and a 200-day moving average price of $5.05. Savara has a one year low of $1.89 and a one year high of $7.01. The company has a debt-to-equity ratio of 0.15, a quick ratio of 11.85 and a current ratio of 11.85. The company has a market capitalization of $1.07 billion, a P/E ratio of -9.91 and a beta of 0.31.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities analysts predict that Savara will post -0.45 EPS for the current fiscal year.

About Savara

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.